CHARACTERIZATION OF RECOMBINANT HIV-1 TAT AND ITS INTERACTION WITH TAR RNA

被引:43
|
作者
SLICE, LW
CODNER, E
ANTELMAN, D
HOLLY, M
WEGRZYNSKI, B
WANG, J
TOOME, V
HSU, MC
NALIN, CM
机构
[1] HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT PROT BIOCHEM,NUTLEY,NJ 07110
[2] HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT VIROL,NUTLEY,NJ 07110
[3] HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT PHYS CHEM,NUTLEY,NJ 07110
关键词
D O I
10.1021/bi00163a014
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant HIV-1 Tat (Tat1-86) has been purified from the cytoplasmic fraction of Escherichia coli without the use of protein denaturants or chaotropic agents. Chloroquine-mediated uptake of the purified protein into cells resulted in transactivation of the HIV LTR promoter. Tat retains 1.64 mol of Zn2+/mol of protein by atomic absorption spectroscopy. Circular dichroism measurements indicated that the structure of recombinant Tat contains 15-20% alpha-helix. Filter binding assays showed that Tat binds to a 63-nucleotide target TAR RNA with a dissociation constant (K(d)) of 10 nM at 25-degrees-C, 0.05 M ionic strength, pH 7.5, in a 1:1 Tat-TAR RNA stoichiometry. Nonelectrostatic interactions provide the principal source of free energy of association. While the pH optimum occurs over a wide H+ concentration, the salt dependence of K(d) indicates formation of a single ion pair. UV-induced protein-RNA cross-linking produced a labeled Tat-TAR RNA adduct, indicating that direct contact occurred between the Tat protein and TAR RNA.
引用
收藏
页码:12062 / 12068
页数:7
相关论文
共 50 条
  • [41] Circular dichroism studies of the interaction of Tat analogues substituted in the Arg52 position with TAR RNA HIV-1
    Mucha, P
    Rekowski, P
    Szyk, A
    Kupryszewski, G
    Giel-Pietraszuk, M
    Barciszewski, J
    LETTERS IN PEPTIDE SCIENCE, 1998, 5 (5-6): : 345 - 348
  • [42] Iron(II) supramolecular helicates interfere with the HIV-1 Tat-TAR RNA interaction critical for viral replication
    Malina, Jaroslav
    Hannon, Michael J.
    Brabec, Viktor
    SCIENTIFIC REPORTS, 2016, 6
  • [43] Circular Dichroism Studies of the Interaction of Tat Analogues Substituted in the Arg52 Position with TAR RNA HIV-1
    Piotr Mucha
    Piotr Rekowski
    Agnieszka Szyk
    Gotfryd Kupryszewski
    Małgorzata Giel-Pietraszuk
    Jan Barciszewski
    Letters in Peptide Science, 1998, 5 : 345 - 348
  • [44] α,α-trehalose derivatives bearing guanidino groups as inhibitors to HIV-1 Tat-TAR RNA interaction in human cells
    Wang, M
    Xu, ZD
    Tu, PF
    Yu, XL
    Xiao, SL
    Yang, M
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (10) : 2585 - 2588
  • [45] CHARACTERIZATION OF A CELL-SURFACE INTERACTION WITH HIV-1 TAT
    SAXINGER, C
    LEE, S
    GALLO, R
    WONGSTAAL, F
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (02) : 196 - 197
  • [46] Circular dichroism studies of the interaction of Tat analogues substituted in the Arg52 position with TAR RNA HIV-1
    Piotr Mucha
    Piotr Rekowski
    Agnieszka Szyk
    Gotfryd Kupryszewski
    Małgorzata Giel-Pietraszuk
    Jan Barciszewski
    Letters in Peptide Science, 1998, 5 : 345 - 348
  • [47] Synthesis and assay of isoquinoline derivatives as HIV-1 Tat-TAR interaction inhibitors
    He, MZ
    Yuan, DK
    Lin, W
    Pang, RF
    Yu, XL
    Yang, M
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (17) : 3978 - 3981
  • [48] A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo
    Lund, LH
    Wahren, B
    Garcia-Blanco, MA
    JOURNAL OF GENERAL VIROLOGY, 2003, 84 : 603 - 606
  • [49] Counterion Redistribution upon Binding of a Tat-Protein Mimic to HIV-1 TAR RNA
    Do, Trang N.
    Ippoliti, Emiliano
    Carloni, Paolo
    Varani, Gabriele
    Parrinello, Michele
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2012, 8 (02) : 688 - 694
  • [50] Molecular basis of HIV-1 TAR RNA specific recognition by an acridine tat-antagonist
    Gelus, N
    Hamy, F
    Bailly, C
    BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (06) : 1075 - 1079